Over one million teeth have been treated with Curodont™, a drill-free solution for early-stage tooth decay, in the United States since January 2024, according to vVARDIS, the Swiss dental company behind the product. The company reports that the treatment has now reached over 420,000 patients and is currently available in nearly 10 percent of U.S. dental offices.
vVARDIS attributes the adoption to a shift toward earlier, non-invasive interventions in caries management. Curodont™ uses a biomimetic formulation designed to work with saliva to support enamel repair, offering dental teams a method to manage incipient carious lesions without the need for drilling or anesthesia.
“Now that Curodont™ is available in nearly 10 percent of U.S. dental offices, an increasing number of dental professionals – or ‘Curodontists’ – are embracing our treatment and giving patients access to this revolutionary solution,” said Haley Abivardi, DMD, co-CEO and co-founder of vVARDIS. “Such high-speed adoption shows how dental professionals have been waiting for decades for a solution that enables them to treat tooth decay at an early stage.”
Goly Abivardi, DMD, co-CEO and co-founder of the company, said, “We are thrilled to witness a ground-breaking transformation in dentistry similar to the advancements that medicine embraced years ago toward non-invasive, early intervention approaches. In the same way, Curodont™ is helping to elevate the standard of care for the early treatment of cavities.”
According to vVARDIS, the treatment process is brief and does not require follow-up appointments, which allows dental professionals to allocate chair time to other procedures.
Several clinicians and academic leaders have expressed support for the product. Dr German O. Gallucci, Chair of the Department of Restorative Dentistry and Biomaterials Sciences at Harvard School of Dental Medicine, said, “Curodont™ is highly effective for treatment of early decays. This new non-invasive therapeutic option is a game changer in the battle against tooth decay.”
Prof. Amid I. Ismail, Dean of the Kornberg School of Dentistry at Temple University, said, “As an epidemiologist and cariologist who has studied dental caries for over four decades and developed guidelines for its diagnosis and management, I can state without hesitation that the advent of Curodont™ represents a significant breakthrough in caries management.”
Timothy Quirt, DDS, MBA, of Heartland Dental, said, “Curodont™ represents a transformative step forward in dentistry. At Heartland Dental, we’ve seen firsthand how this innovation empowers clinicians to treat early-stage caries non-invasively, improving outcomes and deepening patient trust.”
Other experts have pointed to the potential public health benefits. Shan K. Bagby, DMD, MHA, FACHE, Brigadier General, USA (Ret.), said, “What makes Curodont™ especially impactful is its potential to reduce tooth decay among vulnerable populations—particularly children and those covered by Medicaid.”
Prof. Avijit Banerjee of King’s College London noted, “Multiple published clinical studies, including systematic meta-analyses, have provided evidence that, unlike conventional topical re-mineralizing agents which primarily act on the surface of the tooth, Curodont™ Repair can treat early decay throughout the depth of the lesion.”
Prof. Ivo Krejci, University of Geneva, added, “Curodont™ is no longer the future. It’s the present and it should be part of the treatment spectrum in every modern dental practice.”
Curodont™ is currently available in the U.S. and Europe, with plans for expanded global distribution.
For additional information, visit www.vVARDIS.com.
